TL;DR: Aetna, a CVS Health company, modified CPB 0884 covering siltuximab (Sylvant) on September 26, 2025. If your team bills J2860 for siltuximab infusions, review your documentation and prior authorization workflows now.
Aetna's updated siltuximab coverage policy under CPB 0884 in the Aetna system affects commercial medical plan billing for HCPCS code J2860 (injection, siltuximab, 10 mg) and the infusion administration codes CPT 96365 and CPT 96413. Siltuximab is an IL-6 antagonist used primarily for Castleman disease, and this policy governs whether your commercial Aetna claims get paid or denied. Medicare members fall under a separate pathway — see Aetna's Medicare Part B criteria directly.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Siltuximab (Sylvant) — CPB 0884 |
| Policy Code | CPB 0884 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | Medium |
| Specialties Affected | Hematology/Oncology, Infusion Therapy, Rheumatology |
| Key Action | Confirm prior authorization is in place and documentation supports medical necessity before billing J2860 on commercial Aetna claims |
Aetna Siltuximab Coverage Criteria and Medical Necessity Requirements 2025
The core of any siltuximab billing dispute comes down to medical necessity. Aetna's coverage policy under CPB 0884 applies to commercial medical plans only. Medicare members are handled separately, and billing the wrong pathway is a fast route to a claim denial.
Siltuximab (Sylvant) is a monoclonal antibody that targets interleukin-6 (IL-6). It carries FDA approval for multicentric Castleman disease (MCD) in adults who are HIV-negative and human herpesvirus-8 (HHV-8)-negative. That narrow indication matters — Aetna's coverage policy ties reimbursement directly to documented diagnosis, and the ICD-10 code list attached to this CPB runs to over 336 codes, many of them oncologic.
Prior authorization is the critical step here. Siltuximab is a high-cost biologic — J2860 bills at 10 mg increments, and typical doses run 11 mg/kg every three weeks. A missed prior auth on a commercial Aetna claim will cost you the entire infusion charge, not just the drug. Get authorization before the first dose, not after.
The ICD-10 code set attached to CPB 0884 is broad. It includes HIV disease (B20), HHV-8 infection codes (B10.89), and a wide range of malignant neoplasm codes across lung, colon, pancreas, and other sites. That breadth reflects the investigational use of siltuximab in conditions beyond MCD. Aetna distinguishes between covered and non-covered indications — your diagnosis code selection signals which side of that line you're on.
Aetna Siltuximab Exclusions and Non-Covered Indications
The real issue with a policy like this is the gap between what the drug is used for clinically and what Aetna will pay for. Siltuximab has been studied in non-small cell lung cancer, pancreatic cancer, ovarian cancer, prostate cancer, and other solid tumors. None of those are FDA-approved indications for Sylvant.
When billing teams see a long ICD-10 list attached to a CPB, the instinct is to assume all those codes are covered. That's the wrong read. Many of the oncology codes in this policy's ICD-10 set are present to identify non-covered or investigational uses. Aetna considers siltuximab experimental or investigational for indications outside its FDA-approved label when clinical evidence doesn't meet their medical necessity threshold.
If your oncology or infusion team is using siltuximab off-label, document the clinical rationale before the claim goes out. An Aetna claim denial for experimental use is harder to overturn than a prior auth denial — you'll need peer-reviewed evidence and a medical director review. Know that before the infusion chair is occupied.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Multicentric Castleman Disease (MCD) — HIV-negative, HHV-8-negative | Covered (when criteria met) | J2860, CPT 96413 or 96365 | Prior authorization required; document HIV/HHV-8 negative status |
| HIV disease / HIV-2 (B20, B97.35) | Context-dependent | B20, B97.35 | Presence of HIV codes may indicate non-covered population for MCD indication |
| HHV-8 infection (B10.89) | Context-dependent | B10.89 | HHV-8-positive status is an exclusion for the MCD coverage indication |
| Malignant neoplasms (lung, colon, pancreas, and others) | Likely investigational/not covered | C34.x, C18.x–C20, C25.x | Off-label oncology use; Aetna coverage not established for these diagnoses |
| Other solid tumors (broad oncology ICD-10 range) | Investigational | See ICD-10 table below | Clinical evidence required; expect prior auth denial without strong documentation |
Aetna Siltuximab Billing Guidelines and Action Items 2025
The effective date of September 26, 2025 is already here. If you haven't reviewed your siltuximab billing workflows against CPB 0884 in the Aetna system, do it now.
| # | Action Item |
|---|---|
| 1 | Confirm prior authorization on every commercial Aetna siltuximab claim. J2860 is a specialty biologic. Aetna requires prior auth for this drug under commercial plans. Pull your open prior auths and verify they cover the current treatment plan — dose, frequency, and diagnosis. |
| 2 | Match your ICD-10 code to the covered indication, not just the clinical scenario. The 336+ ICD-10 codes in this policy are not all covered. Use the diagnosis code that reflects the FDA-approved indication (MCD) when that is the documented clinical situation. Don't use a broader oncology code if the treating diagnosis is MCD. |
| 3 | Document HIV and HHV-8 status in the medical record before billing. Aetna's MCD coverage requires the patient be HIV-negative and HHV-8-negative. If that documentation isn't in the chart, you have a medical necessity problem before the claim ever leaves your system. |
| 4 | Bill infusion administration with the correct CPT code. Use CPT 96413 for chemotherapy administration, intravenous infusion, up to one hour, for the siltuximab infusion itself. Use CPT 96365 for non-chemotherapy IV infusion billing when that fits the clinical context. Don't mix these up — Aetna's claim editing looks at the drug type and the administration code together. |
| 5 | Flag off-label use claims for compliance review before submission. If your clinical team is administering siltuximab for a solid tumor or other non-MCD indication, loop in your compliance officer before billing. Off-label biologics on commercial Aetna plans without supporting clinical evidence are a denial waiting to happen — and a potential audit risk. |
| 6 | Separate the Medicare workflow completely. CPB 0884 does not govern Medicare members. If you bill Medicare Advantage or traditional Medicare through Aetna, the coverage criteria come from a different source. Mixing commercial and Medicare criteria is one of the more common billing errors on specialty drug claims. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Siltuximab (Sylvant) Under CPB 0884
HCPCS Codes — Covered When Selection Criteria Are Met
| Code | Type | Description |
|---|---|---|
| J2860 | HCPCS | Injection, siltuximab, 10 mg |
CPT Codes — Infusion Administration
| Code | Type | Description |
|---|---|---|
| CPT 96413 | CPT | Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug |
| CPT 96365 | CPT | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
These two CPT codes are listed as "other CPT codes related to the CPB" — meaning they support the claim but the coverage determination centers on J2860 and the diagnosis. Get both right.
Key ICD-10-CM Diagnosis Codes
The full ICD-10 list attached to CPB 0884 runs over 336 codes. Below are the codes explicitly provided in the policy data. These span the covered MCD-related indications and the broader investigational context.
| Code | Description |
|---|---|
| B10.89 | Other human herpesvirus infection |
| B20 | Human immunodeficiency virus [HIV] disease |
| B97.35 | Human immunodeficiency virus, type 2 [HIV-2] as the cause of diseases classified elsewhere |
| C00.0–C14.8 | Malignant neoplasm of lip, oral cavity, and pharynx |
| C18.0–C20 | Malignant neoplasm of colon, rectosigmoid junction, or rectum |
| C22.1 | Intrahepatic bile duct carcinoma |
| C25.0–C25.9 | Malignant neoplasm of pancreas (multiple subsites) |
| C34.0–C34.59 | Malignant neoplasm of bronchus and lung — non-small cell lung cancer (multiple subsites) |
The lung cancer codes alone run from C34.0 through C34.59 — dozens of subcategory codes covering laterality and subsite. Their presence in this policy does not mean Aetna covers siltuximab for non-small cell lung cancer. It means these codes are tracked in the policy framework, most likely as investigational use identifiers.
If your billing team is using any of the C-range codes on a siltuximab claim, treat that as a flag for prior authorization documentation review before submission.
Get the Full Picture for CPT 96365
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.